Atossa Therapeutics, Inc.
(NASDAQ : ATOS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
ABTAbbott Laboratories 0.17%106.840.8%$726.74m
TMOThermo Fisher Scientific, Inc. -0.89%429.071.0%$630.35m
MDTMedtronic Plc -0.19%107.610.6%$545.96m
ISRGIntuitive Surgical, Inc. -3.72%655.572.4%$439.60m
DHRDanaher Corp. -0.53%206.050.7%$411.85m
BDXBecton, Dickinson & Co. 1.80%231.901.0%$405.44m
INOInovio Pharmaceuticals, Inc. 8.49%17.005.9%$375.99m
QDELQuidel Corp. 10.87%189.317.7%$369.77m
DXCMDexCom, Inc. 0.80%389.317.9%$302.80m
SYKStryker Corp. -2.55%206.181.3%$277.61m
BSXBoston Scientific Corp. -2.98%38.491.0%$275.36m
VARVarian Medical Systems, Inc. -0.45%172.729.1%$271.99m
BAXBaxter International, Inc. 0.75%82.941.8%$251.90m
ALGNAlign Technology, Inc. -2.15%320.976.4%$227.10m
EWEdwards Lifesciences Corp. -0.56%83.220.4%$220.20m

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.